← All companies
RXRX annual net income
RECURSION PHARMACEUTICALS, INC.
RXRX - CIK 0001601830
Market cap$1.61 B
Rank#2258
SEC filings908
RECURSION PHARMACEUTICALS, INC. net income by year
RECURSION PHARMACEUTICALS, INC. (RXRX) reported net income of -$644.76M for fiscal year 2025, as filed in its audited annual report with the SEC.
RXRX net income 2019-2025
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$644.76M | -39.1% |
| FY 2024 | -$463.66M | -41.3% |
| FY 2023 | -$328.07M | -37.0% |
| FY 2022 | -$239.48M | -28.4% |
| FY 2021 | -$186.48M | -114.3% |
| FY 2020 | -$87.01M | -40.6% |
| FY 2019 | -$61.88M | - |
Net Income of similar companies
Frequently asked questions
How much profit does RECURSION PHARMACEUTICALS, INC. make?
RECURSION PHARMACEUTICALS, INC. (RXRX) reported net income of -$644.76M for fiscal year 2025, as filed in its audited annual report with the SEC.
How has RECURSION PHARMACEUTICALS, INC.'s net income changed over time?
Between fiscal 2019 and fiscal 2025, RECURSION PHARMACEUTICALS, INC.'s net income declined from -$61.88M to -$644.76M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.